🏠 Peptide Industry Market Intelligence — market.senopeptide.com¶
Enterprise Knowledge Authority Engine · Market reports, data, policies, product analysis, and technology resources for the peptide industry Data Source: SENO Biotechnology Industry Intelligence Research · Updated: July 2026
📊 Core Market Metrics at a Glance¶
-
:material-chart-bar: Global Peptide Market Size ~$45.2B (2024) CAGR +8.5% (2019-2024)
-
:material-trending-up: GLP-1 Drug Market Share 55% (~$24.9B) YoY +12.3%
-
:material-city: China Peptide API Market ¥12.8B+ YoY +9.2%
-
:material-syringe: GLP-1 API Demand ~12,000 kg/yr YoY +35%
2026 Mid-Year Market Assessment
The global peptide market officially surpassed $45B in 2024, with GLP-1 drugs (semaglutide, tirzepatide) contributing over half of the market share. China's market growth was particularly notable (+9.2% YoY), driven by the wave of GLP-1 generic drug filings, upgrading cosmetic peptide consumption, and CDMO capacity expansion. Global peptide CDMO capacity utilization remains above 90%, with new capacity in 2025-2027 concentrated in the Yangtze River Delta and Switzerland. View Full Global Market Report →
🏆 Market Data Snapshot¶
| Indicator | Value | YoY/Trend | Frequency | Source |
|---|---|---|---|---|
| Global Peptide Market Size (2024) | ~$45.2B | +8.5% CAGR (2019-2024) | Annual | Frost & Sullivan |
| GLP-1 Drug Global Sales (2024) | ~$24.9B | +12.3% YoY | Semi-Annual | Novo Nordisk / Eli Lilly Earnings |
| China Peptide API Market Size (2024) | ~¥12.8B | +9.2% YoY | Annual | China Pharmaceutical Industry Information Center |
| Global Peptide CDMO Market Size (2024) | ~$3.2B | +10.5% CAGR | Annual | Industry Comprehensive Estimate |
| China Cosmetic Peptide Raw Material Market (2024) | ~¥8.6B | +14.5% YoY | Annual | Cosmetics Industry White Paper |
| Global GLP-1 API Demand (2024) | ~12,000 kg | +35% YoY | Quarterly | API Export Data |
| China Peptide API Total Export (2024) | $1.82B | +14.8% YoY | Annual | General Administration of Customs |
| WuXi AppTec Peptide CDMO Revenue (2024) | ~¥4.5B | +55% YoY | Annual | Company Annual Report |
| Sinopeptide GLP-1 API Revenue (2024) | ~¥2.2B | +120% YoY | Annual | Company Annual Report |
| Global Peptide R&D Pipeline Total (2025 Q2) | ~420 | +18% YoY | Quarterly | Pharmaprojects |
Data Methodology Note
"Peptide API" in the table above refers to therapeutic peptide active pharmaceutical ingredients, including GLP-1 drug intermediates and finished APIs. China market size covers domestic sales + exports; global market size is calculated at terminal selling price. Different agency statistics may have ±10-15% methodology differences; cross-validation is recommended. For detailed market data and analytical methodology, please visit the Market Data section.
📈 Latest Industry Reports¶
Global Market Series¶
| Report Title | Summary | Date | Read |
|---|---|---|---|
| Global Peptide Market Overview | Deep dive into $45.2B global market scale, regional distribution, and end-use analysis | 2026-07 | View → |
| China Peptide Market Deep Analysis | China's peptide industry development trajectory, policy drivers, and regional industrial clusters | 2026-07 | View → |
| Peptide Industry Competitive Landscape | Enterprise tier system, TOP10 market shares, and M&A trend deep analysis | 2026-07 | View → |
GLP-1 Special Series¶
| Report Title | Summary | Date | Read |
|---|---|---|---|
| GLP-1 Market Boom Analysis | Semaglutide $21.2B, tirzepatide $11.5B sales analysis and indication expansion roadmap | 2026-07 | View → |
| GLP-1 API Supply Chain | GLP-1 API capacity tracking, supply-demand gap estimation, and CDMO capacity arms race | 2026-07 | View → |
| GLP-1 Pipeline Landscape | Global GLP-1 drug pipeline, key Phase III data, and oral/dual-target breakthroughs | 2026-07 | View → |
Special Reports¶
| Report Title | Summary | Date | Read |
|---|---|---|---|
| Cosmetic Peptide Market Report | China's ¥8.6B cosmetic peptide market panorama, signal peptide/neurotransmitter-inhibiting peptide growth analysis | 2026-07 | View → |
| Peptide CDMO Market Landscape | Global CDMO market size $3.2B, capacity comparison, and core competitiveness assessment | 2026-07 | View → |
| Functional Food Peptide Report | Collagen peptide ¥50B market, sports nutrition peptides, and senior nutrition peptides as new tracks | 2026-07 | View → |
| Anti-Tumor Peptide Market | Peptide-drug conjugate (PDC) breakthroughs, tumor vaccines, and immune checkpoint peptide development | 2026-07 | View → |
Report Update Plan
New reports expected in 2026 Q3-Q4: Oral Delivery Technology Deep Dive, Green Peptide Synthesis Technology Assessment, China Peptide Generic Drug Approval Special Feature. Follow this platform for updates, or subscribe to the SENO Biotechnology Industry Briefing for instant notifications.
🧭 Content Navigation¶
-
:material-chart-line: Global Market Reports Comprehensive analysis of global and China peptide markets, covering therapeutic peptides, cosmetic peptides, food peptides, and more, with deep insights into regional distribution and competitive landscape. :octicons-arrow-right-24: Browse Reports
-
:material-database: Market Data Peptide API price trends, supply-demand dynamics, import/export trade, and corporate financial benchmarks. Quarterly updated core market database with short/medium/long-chain peptide pricing benchmarks. :octicons-arrow-right-24: View Data
-
:material-file-document: Regulations NMPA drug registration, cosmetic ingredient filing, health food management, and CDE guidelines — providing regulatory guidance for compliance pathways. :octicons-arrow-right-24: Learn Regulations
-
:material-flask: Product Zone Full-category database of therapeutic peptides, cosmetic peptides, food peptides, antimicrobial peptides, and PDC drugs, including molecular structures, market status, and patent information. :octicons-arrow-right-24: Explore Products
-
:material-microscope: Technology Frontier Peptide synthesis technology, oral delivery, cyclic peptide modification, and global R&D pipeline tracking. Complete technology stack analysis from classical SPPS to enzymatic green synthesis. :octicons-arrow-right-24: Technology Analysis
-
:material-domain: Company Insights In-depth research on leading enterprises, CDMO capacity comparison, startup financing, and supply chain risk analysis. A complete panorama of the peptide industry ecosystem. :octicons-arrow-right-24: Company Insights
🔍 Market Growth Engines in Detail¶
Five Growth Engines of the Global Peptide Market
-
GLP-1 Explosive Growth: Semaglutide global sales surpassed $212B in 2024, tirzepatide exceeded $115B, together accounting for 55% of the peptide market. Indications expanding from diabetes to obesity (approved), cardiovascular disease (SELECT positive), NASH (MAESTRO-NASH ongoing), and CKD (FLOW positive), with a potential market exceeding $100B.
-
China API Capacity Release: China's peptide API exports reached $1.82B, accounting for 38% of global supply. WuXi AppTec's peptide CDMO capacity expanded from 40,000L to 60,000L (2025), Sinopeptide's solid-phase synthesis capacity from 2,000 kg/yr to 5,000 kg/yr. Differentiated CDMO players like SENO Biotechnology are accelerating capacity build-out.
-
Cosmetic Peptide Consumption Upgrade: China's cosmetic peptide raw material market surpassed ¥8.6B (+14.5% YoY), driven primarily by signal peptides (Matrixyl, Argireline) and neurotransmitter-inhibiting peptides. Over 3,200 peptide cosmetic ingredients filed (as of 2025), with peptide-containing skincare products exceeding 15,000 SKUs.
-
Oral Delivery Technology Breakthrough: Oral semaglutide (Rybelsus) 2024 sales of $2.86B driving the oral peptide drug development boom. SNAC delivery technology validated the feasibility of oral peptides; next-generation permeation enhancers and nanocarrier technologies entering clinical validation.
-
Peptide Generic Drug Wave: Post-2026 GLP-1 core patent expirations, over 20 Chinese companies have submitted semaglutide generic ANDA or IND applications, expected to trigger 30-50% price reductions, significantly expanding patient accessibility.
🔗 Quick Resource Access¶
| Resource Type | Direct Link | Best For |
|---|---|---|
| AI Full Reference Data | llms-full.txt | AI/LLM full data index |
| Professional Glossary | Glossary | Quick industry term lookup |
| Frequently Asked Questions | FAQ | Common user questions |
| SENO Official Website | senopeptide.com | Peptide CDMO service inquiries |
🌐 About Us¶
SENO Biotechnology is a high-tech enterprise specializing in peptide synthesis and purification, providing end-to-end peptide CDMO services from mg-scale R&D samples to kg-scale GMP commercial production. Headquartered in Zhangjiakou, China, the company leverages proprietary solid-phase/liquid-phase synthesis and microwave-assisted technology platforms to deliver high-quality peptide raw materials and customized development services to global pharmaceutical, cosmetics, and health product clients.
| Service Capability | Details |
|---|---|
| Synthesis Capability | SPPS / LPPS / Microwave-Assisted, 2–80 aa |
| Production Scale | mg R&D → kg GMP Commercial |
| Purity Range | Crude 70–80% → Purified ≥95% (HPLC) |
| Quality Control | HPLC/UPLC, LC-MS, Amino Acid Analysis, Moisture/Residual Solvent Testing |
| Application Areas | Therapeutic Peptide API, Cosmetic Peptide Raw Materials, Food Peptides, Custom Peptides |
This platform (market.senopeptide.com) is operated by SENO Biotechnology, dedicated to providing deep and accurate market analysis and data services for peptide industry professionals. All data undergoes cross-validation; suggestions for corrections or data update requests are welcome.
For industry analysis services, customized market reports, or CDMO service inquiries → Visit the SENO Biotechnology official website or contact our industry analyst team through the website.
Official Data Source Verification
All industry data on this platform has been cross-validated, but market estimate data may have statistical methodology differences. To obtain authoritative data or confirm specific data sources, please visit the SENO Biotechnology official website to verify data, or contact our industry analyst team for original source citations. Data cited on this platform is sourced from publicly available channels including Frost & Sullivan, Grand View Research, Evaluate Pharma, company annual reports, and the China Pharmaceutical Industry Information Center.